The treatment of atopic dermatitis with topical immunomodulators

Clinics in Dermatology

Volumn 21, Issue 3, 2003, Pages 215-224

  Tomi, Nordwig S ^b   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN E RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; LACTAM DERIVATIVE; LEFLUNOMIDE; MACROPHILIN 12; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PROTEIN; RAPAMYCIN; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CELL ACTIVATION; CHRONIC DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); COUGHING; CREAM; DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; ECZEMA; ERYTHEMA; ERYTHRODERMA; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEAT SENSATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LANGERHANS CELL; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; NETHERTON DISEASE; NEUROLOGIC DISEASE; OINTMENT; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PYRIMIDINE SYNTHESIS; RECURRENT DISEASE; RHINOPHARYNGITIS; SKIN BURNING SENSATION; SKIN DISEASE; STRUCTURE ANALYSIS; T LYMPHOCYTE; TACHYPHYLAXIS; ULTRAVIOLET B RADIATION; VOMITING;

EID: 0038392777     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00367-X     Document Type: Article

References (98)

1. Rudikoff D., Lebwohl M. Atopic dermatitis. Lancet. 351:1998;1715-1721.
2. Coca A.F., Cooke R.A. On the classification of the phenomenon of hypersensitiveness. J Immunol. 8:1923;163-182.
3. Leung D.Y., Bhan A.K., Schneeberger E.E., Geha R.S. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol. 71:(1 pt 1):1983;47-56.
4. Taylor R.S., Baadsgaard O., Hammerberg C., Cooper K.D. Hyperstimulatory CD1a+CD1b+CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis. J Immunol. 147:1991;3794-3802.
5. Bieber T., Rieger A., Neuchrist C., et al. Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon. J Exp Med. 170:1989;309-314.
6. Wollenberg A., Kraft S., Hanau D., Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol. 106:1996;446-453.
7. Leiferman K.M., Ackerman S.J., Sampson H.A., et al. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis comparison with onchocerciasis . N Engl J Med. 313:1985;282-285.
8. Damsgaard T.E., Olesen A.B., Sorensen F.B., et al. Mast cells and atopic dermatitis stereological quantification of mast cells in atopic dermatitis and normal human skin . Arch Dermatol Res. 289:1997;256-260.
9. Werner Y., Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol. 65:1985;102-105.
10. Hara J., Higuchi K., Okamoto R., et al. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol. 115:2000;406-413.
11. Thepen T., Langeveld-Wildschut E.G., Bihari I.C., et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ an immunocytochemical study . J Allergy Clin Immunol. 97:1996;828-837.
12. Cooper K.D., Stevens S.R. T cells in atopic dermatitis. J Am Acad Derm. 45:2001;510-513.
13. Muro Y. Autoantibodies in atopic dermatitis. J Dermatol Sci. 25:2001;171-178.
14. Valenta R., Seiberler S., Natter S., et al. Autoallergy a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol. 105:2000;432-437.
15. Valenta R., Natter S., Seiberler S., et al. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol. 111:1998;1178-1183.
16. Brehler R., Luger T.A. Atopy immunodeviation and environment . J Allergy Clin Immunol. 104:1999;1128-1130.
17. Akdis M., Trautmann A., Klunker S., et al. Cytokine network and dysregulated apoptosis in atopic dermatitis. Acta Odontol Scand. 59:2001;178-182.
18. Schwarz T. No eczema without keratinocyte death. J Clin Invest. 106:2000;9-10.
19. Hill C.J., Rostenberg A. Jr. Adverse effects from topical steroids. Cutis. 21:1978;624-628.
20. Carnahan M.C., Goldstein D.A. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 11:2000;478-483.
21. McLean C.J., Lobo R.F., Brazier D.J. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet. 345:1995;330.
22. Queille C., Pommarede R., Saurat J.H. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1:1984;246-253.
23. Ruiz-Maldonado R., Zapata G., Lourdes T., Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. 136:1982;274-275.
24. Aoyama H., Tabata N., Tanaka M., et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol. 133:1995;494-496.
25. Krutmann J. Phototherapy for atopic dermatitis. Dermatol Ther. 1:1996;24-31.
26. Luger T.A. Treatment of immune-mediated skin diseases future perspectives . Eur J Dermatol. 11:2001;343-347.
27. Laan R.F.J.M., van Riel P.L.C.M., van de Putte L.B.A. Leflunomide and Methotrexate. Curr Opin Rheumatol. 13:2001;159-163.
28. Nousari H.C., Sragovich A., Kimyai-Asadi A. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 40:1999;265-268.
29. Mizoguchi M., Kawaguchi K., Ohsuga Y., et al. Cyclosporin ointment for psoriasis and atopic dermatitis. Lancet. 339:1992;1120.
30. Schöpf R.E. Pimecrolimus. Curr Opin Investig Drugs. 3:2002;720-724.
31. Bieber T. Topical tacrolimus (FK 506) a new milestone in the management of atopic dermatitis . J Allergy Clin Immunol. 102:1998;555-557.
32. Reitamo S. Tacrolimus a new topical immunomodulatory therapy for atopic dermatitis . J Allergy Clin Immunol. 107:2001;445-448.
33. Banerji S.S., Parsons J.N., Tocci M.J. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol. 11:1991;4074-4087.
34. Tocci M.J., Matkovich D.A., Collier K.A., et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 143:1989;718-726.
35. Stuetz A., Grassberger M., Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981) preclinical pharmacological profile and skin selectivity . Semin Cutan Med Surg. 20:2001;233-241.
36. Michel G., Kemeny L., Homey B., Ruzicka T. FK 506 in the treatment of inflammatory skin diseases promises and perspectives . Immunol Today. 17:1996;106-108.
37. Meingassner J.G., di Padova F., Hiestand P., et al. Pimecrolimus (Elidel, SDZ ASM 981) in contrast to cyclosporin A and tacrolimus, is highly effective in animal models of skin inflammation but has only low activity in models indicating immunosuppressive potential. Pediatr Dermatol. 18:(Suppl):2001;76.
38. Kaye R.E., Fruman D.A., Bierer B.E., et al. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12 . Proc Natl Acad Sci U S A. 89:1992;8542-8546.
39. Wollenberg A., Sharma S., von Bubnoff D., et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 107:2001;519-525.
40. Bieber T. Fc epsilon RI-expressing antigen-presenting cells new players in the atopic game . Immunol Today. 18:1997;311-313.
41. Wollenberg A., Wen S., Bieber T. Phenotyping of epidermal dendritic cells clinical applications of a flow cytometric micromethod . Cytometry. 37:1999;147-155.
42. Grewe M., Gyufko K., Schopf E., Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet. 343:1994;25-26.
43. Grassberger M., Baumruker T., Enz A., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases in vitro pharmacology . Br J Dermatol. 141:1999;264-273.
44. Paul C., Graeber M., Stuetz A. Ascomycins promising agents for the treatment of inflammatory skin diseases . Expert Opin Investig Drugs. 9:2000;69-77.
45. van der Heijden F.L., Wierenga E.A., Bos J.D., Kapsenberg M.L. High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol. 97:1991;389-394.
46. Bochelen D., Rudin M., Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther. 288:1999;653-659.
47. Zuberbier T., Chong S.U., Grunow K., et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 108:2001;275-280.
48. Hultsch T., Mueller K.D., Meingassner J.G., et al. Ascomycin macrolactam derivate SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL2HS mas cells in an immunophilin-dependent manner. Arch Dermatol Res. 290:1998;501-507.
49. Kehren J., Cordier A., Polymeropoulos M., et al. Gene profiling of blood cells from psoriatic patients after oral treatment with SDZ ASM 981. J Invest Dermatol. 117:2001;545.
50. Neckermann G., Bavandi A., Meingassner J.G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol. 142:2000;669-679.
51. Sengoku T., Morita K., Sakuma S., et al. Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. Eur J Pharmacol. 379:1999;183-189.
52. Lauerma A.I., Maibach H.I., Granlund H., et al. Inhibition of contact allergy reactions by topical FK506. Lancet. 340:1992;556.
53. Reitamo S., Rissanen J., Remitz A., et al. Tacrolimus ointment does not affect collagen synthesis results of a single-center randomized trial . J Invest Dermatol. 111:1998;396-398.
54. Queille-Roussel C., Paul C., Duteil L., et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks a randomized, double-blind controlled study . Br J Dermatol. 144:2001;507-513.
55. Drake L., Prendergast M., Maher R., et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 44:(1 Suppl):2001;S65-72.
56. Sugiura H., Uehara M., Hoshino N., Yamaji A. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol. 136:2000;1062-1063.
57. Reitamo S., Wollenberg A., Schopf E., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis the European Tacrolimus Ointment Study Group . Arch Dermatol. 136:2000;999-1006.
58. Alaiti S., Kang S., Fiedler V.C., et al. Tacrolimus (FK506) ointment for atopic dermatitis a phase I study in adults and children . J Am Acad Dermatol. 38:1998;69-76.
59. Ruzicka T., Bieber T., Schopf E., et al. A short-term trial of tacrolimus ointment for atopic dermatitis European Tacrolimus Multicenter Atopic Dermatitis Study Group . N Engl J Med. 337:1997;816-821.
60. Kang S., Lucky A.W., Pariser D., et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 44:(1 Suppl):2001;S58-64.
61. Paller A., Eichenfield L.F., Leung D.Y., et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 44:(1 Suppl):2001;S47-57.
62. Boguniewicz M., Fiedler V.C., Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Pediatric Tacrolimus Study Group . J Allergy Clin Immunol. 102:(4 Pt 1):1998;637-644.
63. Yamamoto T., Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol. 80:2001;451.
64. Lener E.V., Brieva J., Schachter M., et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol. 137:2001;419-422.
65. Choi C.J., Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. Arch Dermatol. 137:2001;1202-1206.
66. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea a preliminary report . J Am Acad Dermatol. 44:2001;995-998.
67. Böhm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of lichen sclerosus et atrophicus with tacrolimus. Arch Derm (in press).
68. Sugiura H., Uehara M., Hoshino N., Yamaji A. An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. Br J Dermatol. 145:2001;795-798.
69. Soter N.A., Fleischer A.B. Jr, Webster G.F., et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part II safety . J Am Acad Dermatol. 44:(1 Suppl):2001;S39-46.
70. Hanifin J., Thurston M., Omoto M., et al. The eczema area and severity index (EASI) assessment of reliability in atopic dermatitis . Exp Dermatol. 10:2001;11-18.
71. Hanifin J.M., Ling M.R., Langley R., et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part I efficacy . J Am Acad Dermatol. 44:(1 Suppl):2001;S28-38.
72. Kawashima M., Nakagawa H., Ohtsuki M., et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet. 348:1996;1240-1241.
73. Nakagawa H., Etoh T., Ishibashi Y., et al. Tacrolimus ointment for atopic dermatitis. Lancet. 344:1994;883.
74. Allen A., Siegfried E., Silverman R., et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 137:2001;747-750.
75. Plosker G.L., Foster R.H. Tacrolimus a further update of its pharmacology and therapeutic use in the management of organ transplantation . Drugs. 59:2000;323-389.
76. Younes B.S., McDiarmid S.V., Martin M.G., et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 70:2000;94-99.
77. Gupta A.K., Adamiak A., Chow M. Tacrolimus: a review of its use for the management of dermatosis. J Europ Acad Derm. 16:2002;100-119.
78. Remitz A., Kyllonen H., Granlund H., Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 107:2001;196-197.
79. Kino T., Hatanaka H., Hashimoto M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, I fermentation, isolation, and physico-chemical and biological characteristics . J Antibiot (Tokyo). 40:1987;1249-1255.
80. Kino T., Hatanaka H., Miyata S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, II immunosuppressive effect of FK-506 in vitro . J Antibiot (Tokyo). 40:1987;1256-1265.
81. Ramsay H.M., Fryer A.A., Reece S., et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis. 36:2000;167-176.
82. Williams H., Pottier A., Strachan D. Are viral warts seen more commonly in children with eczema? Arch Dermatol. 129:1993;717-720.
83. Van Leent E.J., Graber M., Thurston M., et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 134:1998;805-809.
84. Luger T., Van Leent E.J., Graeber M., et al. SDZ ASM 981 an emerging safe and effective treatment for atopic dermatitis . Br J Dermatol. 144:2001;788-794.
85. Paller A., Hedgecock S., Marshall K., et al. Elidel superior efficacy and safety in infants and children with atopic dermatitis . Pediatr Dermatol. 18:(Suppl):2001;133. Abstract.
86. De Prost Y., Wahn U. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% provides safe and effective long-term management of atopic dermatitis in children in a 12-month controlled study, reducing the need for topical corticosteroids usage. Pediatr Dermatol. 18:(Suppl):2001;75. Abstract.
87. Boguniewicz M., Eichenfeld L., Honig P., et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is safe in long-term use in pediatric atopic dermatitis. Pediatr Dermatol. 18:(Suppl):2001;76. Abstract.
88. Papp K., Ho V., Halber A., et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis. Pediatr Dermatol. 18:(Suppl):2001;76. Abstract.
89. Kapp A., Papp K., Bingham A., et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 110:2002;277-284.
90. Wahn U., Kapp A., Molloy S., et al. Elidel shifting the paradigm of pediatric atopic dermatitis management - a long-term approach . Pediatr Dermatol. 18:(Suppl):2001;133. Abstract.
91. Cherill R., Tofte S., MacNaul R., et al. SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. J Europ Acad Derm. 14:2000;128.
92. Queille-Roussel C., Graeber M., Thurston M., et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm. 42:2000;349-350.
93. Rappersberger K., Komar M., Ebelin M.E., et al. Oral SDZ ASM 981 safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque type psoriasis . J Invest Dermatol. 114:2000;776.
94. Wahn U., Bos J.D., Goodfield M., et al. Efficacy and Safety of Pimecrolimus Cream in Long-Term Management of Atopic Dermatitis in Children. Pediatrics. 110:2002;1-8.
95. Whalley D., McKenna S., Huels J., et al. The benefit of pime- crolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of pediatric atopic dermatitis results of two 6-week randomized double-blind, vehicle-controlled clinical trials in the US . Pediatr Dermatol. 18:(Suppl):2001;77. Abstract.
96. Lakhanpaul M., Wahn U., Pariser D., et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% minimal systemic absorption in infants with extensive atopic dermatitis . Pediatr Dermatol. 18:(Suppl):2001;78. Abstract.
97. Harper J., Allen R., Wahn U., et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% consistently low blood concentrations in children with extensive atopic dermatitis . Pediatr Dermatol. 18:(Suppl):2001;78. Abstract.
98. Harper J., Green A., Scott G., et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 144:2001;781-787.